Anti-AICDA antibody [5G9] - BSA and Azide free
- KO Validated
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(1 Publication)
Knockout Tested Rat Recombinant Monoclonal AICDA antibody. Carrier free. Suitable for WB, Flow Cyt (Intra) and reacts with Human, Mouse samples. Cited in 1 publication.
View Alternative Names
AID, AICDA, Single-stranded DNA cytosine deaminase, Activation-induced cytidine deaminase, Cytidine aminohydrolase
- Flow Cyt (Intra)
Unknown
Flow Cytometry (Intracellular) - Anti-AICDA antibody [5G9] - BSA and Azide free (AB255769)
Intracellular flow cytometric analysis of 4% paraformaldehyde fixed 90% methanol permeabilized K-562 (human chronic myelogenous leukemia lymphoblast, Left) / Ramos (human Burkitt's lymphoma B lymphocyte, Right) cells labelling AICDA with ab252813 at 0.316μg/mL (Red) compared with a rat monoclonal IgG (Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). A Goat anti rat IgG (Alexa Fluor® 488, ab150157) at 1/2000 dilution was used as the secondary antibody. Negative control : K-562.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab252813).
- WB
Lab
Western blot - Anti-AICDA antibody [5G9] - BSA and Azide free (AB255769)
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab252813). False colour image of Western blot : Anti-AICDA antibody [5G9] staining at 1.264 ug/ml, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab252813 was shown to bind specifically to AICDA. A band was observed at 22 kDa in wild-type Raji cell lysates with no signal observed at this size in AICDA knockout cell line ab277185 (knockout cell lysate ab277227). To generate this image, wild-type and AICDA knockout Raji cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rat IgG H&L (IRDye® 800CW) preabsorbed (ab253031) and Goat anti-Rabbit IgG H&L 680RD at 1/20000 dilution.
All lanes:
Western blot - Anti-AICDA antibody [5G9] (<a href='/en-us/products/primary-antibodies/aicda-antibody-5g9-ab252813'>ab252813</a>) at 1.264 µg/mL
Lane 1:
Wild-type Raji cell lysate at 20 µg
Lane 2:
AICDA knockout Raji cell lysate at 20 µg
Lane 3:
Daudi cell lysate at 20 µg
Lane 4:
SH-SY5Y cell lysate at 20 µg
Predicted band size: 23 kDa
Observed band size: 22 kDa
false
- WB
Lab
Western blot - Anti-AICDA antibody [5G9] - BSA and Azide free (AB255769)
Blocking and diluting buffer and concentration : 5% NFDM/TBST.
Negative control : K562 (PMID : 27217538).
Exposure time : 59 seconds.
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab252813).
All lanes:
Western blot - Anti-AICDA antibody [5G9] (<a href='/en-us/products/primary-antibodies/aicda-antibody-5g9-ab252813'>ab252813</a>) at 1.264 µg/mL
Lane 1:
NAMALWA (human Burkitts lymphoma B lymphocyte), whole cell lysate at 10 µg
Lane 2:
Raji (human Burkitts lymphoma B lymphocyte), whole cell lysate at 10 µg
Lane 3:
K562 (human chronic myelogenous leukemia lymphoblast), whole cell lysate at 10 µg
Lane 4:
WEHI-231 (mouse B cell lymphoma B lymphocyte), whole cell lysate at 10 µg
Secondary
All lanes:
Western blot - Goat Anti-Rat IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rat-igg-h-l-hrp-ab205720'>ab205720</a>) at 1/2000 dilution
Predicted band size: 23 kDa
Observed band size: 23 kDa
false
Related conjugates and formulations (1)
-
Anti-AICDA antibody [5G9]
Reactivity data
Product details
ab255769 is the carrier-free version of ab252813.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
AICDA plays an important role in the adaptive immune system by facilitating the diversification of antibodies. It does not appear to function as part of a larger protein complex but operates independently to induce mutations in variable regions of immunoglobulin genes. This activity enables B cells to produce antibodies with higher affinity and different isotypes important for an effective immune defense system. AICDA’s function ensures the generation of diverse antibody repertoires allowing the immune system to effectively target a wide range of pathogens.
Pathways
AICDA is integral to the immunoglobulin gene diversification pathway. It initiates somatic hypermutation and class switch recombination by deaminating cytosine residues in the DNA of immunoglobulin genes. This action relates AICDA to other proteins involved in DNA repair and error-prone replication such as uracil-DNA glycosylase (UNG) and the mismatch repair proteins like MSH2 and MSH6. AICDA's deamination activity triggers the recruitment of these proteins to introduce mutations and remove uracil residues facilitating the generation of antibody diversity.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (1)
Recent publications for all applications. Explore the full list and refine your search
The Journal of pathology 205:541-7 PubMed15732141
2005
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com